Most Read Articles
5 days ago
A strong belief in the necessity of medication is associated with better adherence to oral disease-modifying antirheumatic drugs (DMARDs) or prednisone, while higher self-efficacy correlates with poor adherence, in a diverse cohort of patients with rheumatoid arthritis (RA), suggests a study.
4 days ago
Low-dose administrations of haloperidol after thoracic surgery does not appear to prevent postoperative delirium, according to a new study.
2 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 4 days ago
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.

Ramucirumab similarly beneficial for Asian patients with advanced HCC

Elaine Soliven
6 days ago
Dr Chia-Jui Yen

Treatment with ramucirumab, a human IgG1 monoclonal antibody, significantly improves overall survival (OS) in patients with advanced hepatocellular carcinoma (HCC) in both Asians and non-Asians, based on a pooled analysis of REACH* and REACH-2** studies presented at ESMO Asia 2018.

“This subgroup analysis demonstrates significant survival benefits of ramucirumab treatment in Asian and non-Asian patients with advanced HCC and alpha-fetoprotein (AFP) level [of] ≥400 ng/mL,” said Dr Chia-Jui Yen from the National Cheng Kung University in Tainan City, Taiwan.

REACH and REACH-2 were comparable trials with similar study design that enrolled 291 Asian and 251 non-Asian patients with HCC who had elevated AFP levels at baseline. Patients were randomized to receive intravenous ramucirumab (8 mg/kg) or placebo every 2 weeks, and all patients received best supportive care. Patients continued treatment until disease progression, unacceptable toxicity, or study withdrawal. [ESMO Asia 2018, abstract 1490]

Both Asian and non-Asian patients demonstrated a significantly higher OS with ramucirumab compared with placebo (median, 8.08 vs 4.76 months, hazard ratio [HR], 0.73, 95 percent confidence interval [CI], 0.56–0.95; log-rank p=0.0189 for Asians and 7.98 vs 5.22 months, HR, 0.65, 95 percent CI, 0.49–0.86; log-rank p=0.0028 for non-Asians).

Patients on ramucirumab also experienced a significantly longer progression-free survival (PFS) than those on placebo (median, 2.73 vs 1.45 months, HR, 0.58, 95 percent CI, 0.44–0.76; log-rank p<0.0001 in Asians and 3.06 vs 1.87 months, HR, 0.55, 95 percent CI, 0.41–0.73; log-rank p<0.0001 in non-Asians).

Higher objective response rate was also observed in the ramucirumab group than the placebo group for both Asians and non-Asians (4.2 percent vs 0.8 percent; p=0.1320 for Asians and 6.8 percent vs 1.0 percent; p=0.0270 for non-Asians).

Similarly, disease control rate was significantly higher in the ramucirumab vs the placebo groups (53.6 percent vs 33.3 percent; p=0.0043 for Asians and 59.5 percent vs 41.70 percent; p=0.0067 for non-Asians).

A higher incidence of grade ≥3 hypertension was observed in both Asians and non-Asians who received ramucirumab compared with placebo (7.7 percent vs 2.5 percent and 16.9 percent vs 4.9 percent, respectively).

“[Nevertheless,] treatment with ramucirumab was well tolerated, with similar safety profiles between Asian and non-Asian patients,” said Yen.

“Ramucirumab represents an important new potential treatment option for Asian patients with HCC and an elevated AFP after prior sorafenib treatment, a population associated with poor prognosis and aggressive disease,” Yen added.

 

*REACH: A study of ramucirumab (IMC-1121B) drug product (DP) and best supportive care (BSC) versus placebo and BSC as 2nd-line treatment in participants with hepatocellular carcinoma after 1st-line therapy with sorafenib

**REACH-2: A study of ramucirumab (LY3009806) versus placebo in participants with hepatocellular carcinoma and elevated baseline alpha-fetoprotein

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
5 days ago
A strong belief in the necessity of medication is associated with better adherence to oral disease-modifying antirheumatic drugs (DMARDs) or prednisone, while higher self-efficacy correlates with poor adherence, in a diverse cohort of patients with rheumatoid arthritis (RA), suggests a study.
4 days ago
Low-dose administrations of haloperidol after thoracic surgery does not appear to prevent postoperative delirium, according to a new study.
2 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 4 days ago
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.